Nona Biosciences and Kodiak Sciences partner to develop novel antibodies for ophthalmic diseases
Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing Nona's Harbour Mice platform, the collaboration aims to accelerate antibody discovery, focusing on innovative therapies for retinal and other eye conditions.
(Image credit: AdobeStock/Mirror-images)
Nona Biosciences has announced a strategic collaboration with Kodiak Sciences Inc. aimed at advancing the discovery of innovative multi-target antibodies for the treatment of ophthalmic diseases. This partnership will utilize Nona's proprietary Harbour Mice platform, a technology for generating fully human antibodies.
The Harbour Mice platform is capable of producing fully human monoclonal antibodies in both the traditional two heavy and two light chain (H2L2) format and the more advanced heavy chain-only (HCAb) format. This approach eliminates the need for further engineering or humanization, streamlining the antibody development process. Notably, the HCAb platform produces heavy chain-only antibodies that are about half the size of conventional IgGs, offering unique advantages for developing next-generation antibody therapies.1
Under the terms of the agreement, Kodiak Sciences will gain access to both the H2L2 and HCAb Harbour Mice platforms for use in multiple therapeutic antibody discovery programs.
Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, expressed excitement about the collaboration, emphasizing the potential for advancing new antibody therapies for retinal and other ophthalmic conditions.
“We are excited to partner with Kodiak Sciences to develop novel therapeutic antibodies for ophthalmic diseases,” said Wang. “This agreement underscores the strength of our Harbour Mice technology and our commitment to advancing next-generation therapies. With Nona’s expertise and cutting-edge platforms, we look forward to helping Kodiak accelerate its antibody development efforts and deliver innovative treatments to patients.”
Victor Perlroth, MD, Chairman and CEO of Kodiak Sciences, highlighted the complexity of retinal diseases and the need for multi-target therapies to effectively address these conditions.
"Retinal diseases are challenging due to their complex causes, so developing effective treatments requires targeting multiple pathways simultaneously," said Perlroth. "Our partnership with Nona Biosciences, leveraging their advanced Harbour Mice platforms and expertise in antibody discovery, will be key to accelerating our work in creating next-generation biotherapeutics. Together, we are poised to bring breakthrough treatments to patients who need them the most.”
